Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest

This study tested whether combining a targeted form of radiation with an immunotherapy drug (durvalumab) is safe and effective for older or frail patients with stage III non-small cell lung cancer (NSCLC) who are not healthy enough for standard chemotherapy. The goal was to see i…

This study tested whether adding an immunotherapy drug (pembrolizumab) to a standard tumor-destroying procedure (ablation) could better control early-stage liver cancer. It involved 30 patients eligible for ablation, aiming to see if the combination could shrink tumors before the…

This study tested a new drug for people with advanced stomach or esophageal cancer that had spread and stopped responding to standard treatments. The drug, called sacituzumab-govitecan, is designed to target cancer cells specifically. Researchers gave the drug to 58 patients to s…

This study created a German registry to collect information about people with bile duct and gallbladder cancers. It tracked what treatments patients received, how they responded, and their quality of life over time. The goal was to gather data to help guide future research and im…